Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 268-211-2 | CAS number: 68037-36-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Repeat dose oral: A recent GLP OECD 422 study in rats showed no adverse effects at the highest dose tested (i.e., 1000 mg/kg bw/day)). Doses included 100, 350, 600 and 1000 mg/kg bw/ day. Test substance-related blue discoloration/contents were observed macroscopically in the stomach, duodenum, jejunum, ileum, cecum, colon, and rectum of all test substance-administered groups at the primary necropsy, which correlated microscopically with blue contents. Blue matting of skin and tail were additionally noted macroscopically at the primary and recovery necropsies. The findings were attributed to the blue color of test substance and were considered to be nonadverse. No test substance-related differences in final body weights or organ weights were noted. There were no adverse test substance-related clinical observations or effects on mean body weights, body weight gains, and food consumption noted at any dosage level. Furthermore, there were no adverse effects on organ weights, clinical pathology parameters, thyroid hormones (males only) or macroscopic/microscopic examination in the F0 males and females at any dosage level. Therefore, the NOAEL for systemic toxicity was considered to be 1000 mg/kg/day.
Repeat dose dermal: WAIVER
Repeat dose inhalation: WAIVER
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 24 Feb 2017 to 28 Mar 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on species / strain selection:
- Sprague Dawley Crl:CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Inc., Raleigh, NC on 28 Feb 2017
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: minimum of 70 days of age
- Weight at study initiation: Male body weights ranged from 331 g to 401 g and female body weights ranged from 234 g to 271 g on Study Day 0.
- Fasting period before study: Not reported
- Housing: Housed 2–3 rats/cage by sex in clean, solid-bottom cages with bedding material (Bed-O' Cobs®; The Andersons, Cob Products Division, Maumee, OH).
- Diet (e.g. ad libitum): PMI Nutrition International, LLC Certified Rodent LabDiet® 5002, provided ad libitum
- Water (e.g. ad libitum): Municipal water, treated with Reverse osmosis-purified (on-site) drinking water, provided ad libitum
- Acclimation period: 14 days
DETAILS OF FOOD AND WATER QUALITY: Feed lots used during the study were documented in
the study records. Feeders were changed and sanitized once per week. Municipal water supplying
the facility was sampled for contaminants according to Charles River SOPs. The results of the diet
and water analyses are maintained at Charles River. No contaminants were present in animal feed or
water at concentrations sufficient to interfere with the objectives of this study.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): f 68°F to 78°F (20°C to 26°C)
- Humidity (%): 30% to 70%
- Air changes (per hr): 10 fresh air changes per hour
- Photoperiod (hrs dark / hrs light): 12-hour light (0600 hours to 1800 hours)/12-hour dark photoperiod
IN-LIFE DATES: From: 24 Feb 2017 To: 28 Mar 2017 - Route of administration:
- oral: gavage
- Details on route of administration:
- The vehicle and test item formulations were administered orally by gavage, via appropriately sized flexible, disposable, plastic feeding tubes once daily for 14 consecutive days (Study Days 0–13). In dividual dosages were based on the most recently recorded body weights to provide the correct mg/kg/day dose. All animals were dosed at approximately the same time each day.
- Vehicle:
- polyethylene glycol
- Remarks:
- Polyethylene glycol (PEG) 400
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: The vehicle suspension was dispensed approximately weekly for administration to the control group (Group 1) and for preparation of the test item formulations; aliquots were prepared for daily dispensation to the control group and stored at room temperature (18ºC to 24ºC). The vehicle was mixed throughout the preparation, sampling, and dose administration procedures.The test item formulations were prepared approximately weekly as single formulations for each dosage level, divided into aliquots for daily dispensation, and stored at room temperature (18ºC to 24ºC). The test item formulations were stirred continuously throughout the preparation, sampling, and dose administration procedures.
VEHICLE
- Justification for use and choice of vehicle (if other than water): Not reported
- Concentration in vehicle: Not reported
- Amount of vehicle (if gavage): dose volume for all groups was 5 mL/kg.
- Lot/batch no. (if required): 2EL0005
- Purity: Not reported - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples for homogeneity and/or concentration determination were collected from the top, middle, and bottom strata of the first 20, 120, and 200 mg/mL dosing formulations and from the middle stratum of the first control and 70 mg/mL dosing formulations. In addition, samples for resuspension homogeneity determinations were collected from the top and bottom strata of an aliquot taken from the first 20, 120, and 200 mg/mL dosing suspensions following room temperature storage for 10 days; aliquots were mixed for a minimum of 30 minutes prior to sample collection. Samples for concentration analysis were also collected from the middle stratum from the third and last preparation of each dosing formulation (including the control group) prepared during the study. One set of samples from each collection was subjected to the appropriate analyses. All remaining samples were stored at room temperature (18ºC to 24ºC) as back-up. All analyses were conducted by the Charles River Analytical Chemistry Department using a high performance liquid chromatography method with ultraviolet absorbance detection.
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- daily
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Remarks:
- 20 mg/mL concentration
- Dose / conc.:
- 350 mg/kg bw/day (nominal)
- Remarks:
- 70 mg/mL concentration
- Dose / conc.:
- 600 mg/kg bw/day (nominal)
- Remarks:
- 120 mg/mL concentration
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- Remarks:
- 200 mg/mL concentration
- No. of animals per sex per dose:
- 15/sex/dose for control and highest dose level.
10/sex/dose for all other dose levels. - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Dosage levels were selected based on the results of a previous 14-day range-finding study in which male and female rats were administered the test substance at dosage levels of 35, 350, 500, and 1000 mg/kg/day. In that study, clinical observations included blue staining or discoloration on the fur, tail, and ears were noted at all dosage levels as a result of discolored excrement. This finding was related to the color of the neat test substance and was not considered adverse. Mean body weights, food consumption, and organ weights were unaffected by treatment. Therefore, dosage levels of 100, 350, 600, and 1000 mg/kg/day were selected for the current study.The selected route of administration for this study was oral (gavage) because this a potential route of exposure for humans. Historically, this route has been used extensively for studies of this nature.
- Rationale for animal assignment (if not random): random assignment - Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Twice daily, once in the morning and once in the afternoon.
- Cage side observations checked: moribundity and mortality
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Daily, prior to dose administration and at appropriate intervals per the study report.
BODY WEIGHT: Yes
- Time schedule for examinations: at appropriate intervals per the study report.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study)
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes, at appropriate intervals per the study report.
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes, Food consumption was normalized to the number of animals/cage and was reported as g/animal/day.
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
- Time schedule for examinations: N/A
OPHTHALMOSCOPIC EXAMINATION: No
- Time schedule for examinations: N/A
- Dose groups that were examined: N/A
HAEMATOLOGY: No
- Time schedule for collection of blood: N/A
- Anaesthetic used for blood collection: N/A
- Animals fasted: N/A
- How many animals: N/A
- Parameters checked: N/A
CLINICAL CHEMISTRY: No
- Time schedule for collection of blood: N/A
- Animals fasted: N/A
- How many animals: N/A
- Parameters checked: N/A
URINALYSIS: No
- Time schedule for collection of urine: N/A
- Metabolism cages used for collection of urine: N/A
- Animals fasted: N/A
- Parameters checked: N/A
NEUROBEHAVIOURAL EXAMINATION: yes
- Time schedule for examinations: At appropriate times.
- Dose groups that were examined: all
- Battery of functions tested: motor activity
IMMUNOLOGY: No
- Time schedule for examinations: N/A
- How many animals: N/A
- Dose groups that were examined: N/A
- Parameters checked: N/A
OTHER: No - Sacrifice and pathology:
- - the necropsy included examination of the external surface, all orifices, the cranial cavity, the external surfaces of the brain and spinal cord, and the thoracic, abdominal and pelvic cavities, including viscera. For females that failed to deliver, a pregnancy status was determined, and specific emphasis was placed on anatomic or pathologic findings that may have interfered with pregnancy. For F0 females that were mated, the number of former implantation sites was recorded.
- Other examinations:
- The following organs were weighed from all animals at the scheduled necropsy: Adrenal glands, Brain, Epididymides, Heart, Kidneys, Liver, Ovaries with oviducts, Pituitary, Prostate with seminal vesicles, Spleen, Testes, Thymus gland, Thyroids with parathyroids, and Uterus.
- Statistics:
- All statistical analyses were conducted using SAS® software.
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no test substance-related alterations in final body weights or organ weights at the scheduled necropsies. However, some statistically significant differences were observed when the control and test substance-treated groups were compared. Higher mean spleen weights (absolute and relative to final body weight) were noted in the 1000 mg/kg/day group females at the primary necropsy. No microscopic correlates were noted and weights were within the historical control database range; higher spleen weights were attributed to biological variability and not related to administration of the test substance. At recovery, statistically lower mean ovaries/oviducts weights (relative to final body weight) were noted in the 1000 mg/kg/day group females. Control and the test substance-administered ovaries/oviducts weights were similar at the primary necropsy, the difference in weight was of minimal magnitude, and weights were within the historical control range; therefore, the difference in weights was attributed to biological variability and not test substance-related. Statistically significantly lower mean thymus weight relative to final body weight was noted in the 1000 mg/kg/day group males at recovery. No thymus weight difference was noted at the primary necropsy and weights were within the historical control range; therefore, the difference in thymus weight was not considered to be test substance-related.
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The test substance-related microscopic findings were noted in the stomach, duodenum, jejunum, ileum, cecum, colon, and rectum of all test substance-administered groups at the primary necropsy. Findings in gastrointestinal tract organs consisted of blue discoloration and/or contents. The findings were attributed to the color of the test substance, and were not considered to be adverse. There were no other test substance-related histologic changes. Remaining histologic changes were considered to be incidental findings or related to some aspect of experimental manipulation other than administration of the test substance. There was no test substance-related alteration in the prevalence, severity, or histologic character of those incidental tissue alterations.
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- not examined
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: absence of effects.
- Critical effects observed:
- no
- Conclusions:
- Administration of the test substance via oral gavage once daily to F0 male rats for a minimum of 14 days prior to mating and continuing throughout mating for a minimum of 28 days and to F0 female rats for 14 days prior to mating and continuing throughout mating, gestation and lactation until 1 day prior to scheduled euthanasia was well tolerated. Test substance-related blue discoloration/contents were observed macroscopically in the stomach, duodenum, jejunum, ileum, cecum, colon, and rectum of all test substance-administered groups at the primary necropsy, which correlated microscopically with blue contents. Blue matting of skin and tail were additionally noted macroscopically at the primary and recovery necropsies. The findings were attributed to the blue color of test substance and were considered to be nonadverse. No test substance-related differences in final body weights or organ weights were noted. NOAEL for F0 systemic toxicity was considered to be 1000 mg/kg/day. The NOAEL for F1 neonatal toxicity was 1000 mg/kg/day based on the absence of effects on F1 offspring at all dosage levels.
- Executive summary:
The objectives of the study were to evaluate the potential toxic effects of the test substance when administered to rats for 28 days and to evaluate the potential of the test substance to affect male and female reproductive performance such as gonadal function, mating behavior, and conception through Day 13 of postnatal life, according to OECD 422. Administration of the test substance via oral gavage once daily to F0 male rats for a minimum of 14 days prior to mating and continuing throughout mating for a minimum of 28 days and to F0 female rats for 14 days prior to mating and continuing throughout mating, gestation and lactation until 1 day prior to scheduled euthanasia was well tolerated. Doses included 100, 350, 600 and 1000 mg/kg bw/ day. Test substance-related blue discoloration/contents were observed macroscopically in the stomach, duodenum, jejunum, ileum, cecum, colon, and rectum of all test substance-administered groups at the primary necropsy, which correlated microscopically with blue contents. Blue matting of skin and tail were additionally noted macroscopically at the primary and recovery necropsies. The findings were attributed to the blue color of test substance and were considered to be nonadverse. No test substance-related differences in final body weights or organ weights were noted.
Under the conditions of this screening study, no test substance-related effects were observed on reproductive performance at any dosage level. Therefore, a dosage level of 1000 mg/kg/day was considered to be the no-observed-adverse-effect level (NOAEL) for F0 reproductive toxicity of the test substance when administered orally by gavage to Crl:CD(SD) rats. There were no adverse test substance-related clinical observations or effects on mean body weights, body weight gains, and food consumption noted at any dosage level. Furthermore, there were no adverse effects on organ weights, clinical pathology parameters, thyroid hormones (males only) or macroscopic/microscopic examination in the F0 males and females at any dosage level. Therefore, the NOAEL for F0 systemic toxicity was considered to be 1000 mg/kg/day. The NOAEL for F1 neonatal toxicity was 1000 mg/kg/day based on the absence of effects on F1 offspring at all dosage levels.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.